APA (7th ed.) Citation

RR, L., M, W., CH, C., SK, H., A, C., K, M., . . . FI, H. (2025). Therapeutic safety implications of SARM1 active site inhibitors: Subinhibitory concentrations cause neurodegeneration. Npj drug discovery, 2(1), . https://doi.org/10.1038/s44386-025-00023-4

Chicago Style (17th ed.) Citation

RR, Leahey, et al. "Therapeutic Safety Implications of SARM1 Active Site Inhibitors: Subinhibitory Concentrations Cause Neurodegeneration." Npj Drug Discovery 2, no. 1 (2025). https://doi.org/10.1038/s44386-025-00023-4.

MLA (9th ed.) Citation

RR, Leahey, et al. "Therapeutic Safety Implications of SARM1 Active Site Inhibitors: Subinhibitory Concentrations Cause Neurodegeneration." Npj Drug Discovery, vol. 2, no. 1, 2025, https://doi.org/10.1038/s44386-025-00023-4.